Covid Drug: New oral antiviral drug likely to get Centre’s approval for treating Covid, Health News, ET HealthWorld

Pune: The Union health ministry is likely to include an oral antiviral drug, nirmatrelvir-ritonavir combination, in the country’s upcoming Covid treatment protocol for patients with mild to moderate disease, who are at high risk of developing severe illness. The combination drug, popularly known by the brand name paxlovid, is currently in high demand in China and a few other nations battling the Covid surge. India’s upcoming Covid treatment protocol is expected to be released within a week. “The combination two-tablet oral drug therapy is likely to be recommended in India…

Read More

Demand for Indian generic drugs skyrockets in China amid Covid surge, Health News, ET HealthWorld

New Delhi: The demand for Indian generic drugs has shot up in China amid the massive COVID surge in the country, with Chinese experts cautioning that fake versions of these drugs are flooding the market. China’s National Health Security Administration said on Sunday that Pfizer‘s Paxlovid oral medication, which is used to treat Covid-19, could not be included in the “register of drugs in the basic medical insurance”, because the company’s quotation was too high, media reports here said. Due to the massive short supply of Paxlovid, demand for Indian…

Read More

Pfizer CEO tests positive for COVID – ET HealthWorld

New York: Pfizer Inc Chief Executive Officer Albert Bourla said on Monday he had tested positive for COVID-19 and was experiencing very mild symptoms. Bourla said he had started a course of the company’s oral COVID-19 antiviral treatment, Paxlovid, and was isolating and following all public health precautions. Paxlovid is an antiviral medication that is used to treat high-risk patients, such as older people. Bourla has received four doses of the COVID vaccine developed by Pfizer and its German partner BioNTech. Follow and connect with us on Twitter, Facebook, Linkedin,…

Read More

Pfizer stops enrollment in Paxlovid trial in standard-risk population – ET HealthWorld

Pfizer Inc said on Tuesday it would halt enrollment in a trial for its COVID-19 antiviral drug, Paxlovid, in standard-risk patients after a study revealed the treatment was not effective in reducing symptoms in that group. The drug has emergency use authorization for high-risk groups in which it has been effective in reducing hospitalizations and deaths. The new data, however, showed a 51% relative risk reduction in standard-risk groups, which the company said was not statistically significant. The standard-risk population usually includes people who do not have health conditions that…

Read More

No merit seen in including Paxlovid in Covid treatment: ICMR – ET HealthWorld

Experts from the Indian Council of Medical Research (ICMR) have not found a compelling reason to include Pfizer’s antiviral drug Paxlovid in the national treatment guidelines for Covid-19. Samiran Panda, head of epidemiology and infectious diseases at ICMR, told ET that members of ICMR’s National Task Force on Covid-19 had met last week to discuss the matter but did not find merit in the drug’s inclusion in the national treatment guidelines for Covid-19. “The current evidence did not merit inclusion of Paxlovid in the treatment guidelines and the existing guidelines…

Read More

ICMR task force meets to discuss inclusion of Pfizer’s Paxlovid for Covid treatment – ET HealthWorld

The Indian Council of Medical Research’s (ICMR) National Task Force on Covid-19 is likely to meet this week to review data available on antiviral drug Paxlovid to decide on its inclusion in the treatment guidelines, people aware of the matter told ET. Last week, India’s drug regulator had approved Pfizer’s Paxlovid for restricted emergency use against Covid-19 amid a rise in infections in the country. Hyderabad-based Hetero Labs will manufacture the generic version of the drug, touted as a game changer in the fight against the disease. “We are regularly…

Read More

Optimus too could launch Covid pill Paxlovid soon – ET HealthWorld

After Hetero Labs, Hyderabad-based Optimus Pharma has got close to launching in the country the generic version of Pfizer‘s antiviral drug Paxlovid, which is being touted as a game changer in the fight against Covid-19. The company has conducted bioavailability and bioequivalence (BA/BE) studies and is likely to submit the safety data to the drug regulator this week for a review, said people aware of the matter. “We have completed our studies and will submit the data this week,” a company executive told ET on condition of anonymity, adding that…

Read More

WHO ‘strongly recommends’ Pfizer’s Covid pill – ET HealthWorld

Geneva, April 21, 2022 -The World Health Organization said Friday it “strongly recommended” Pfizer‘s Covid-19 antiviral pill Paxlovid for patients with milder forms of the disease who were still at a high risk of hospitalisation. However the UN agency warned it was “extremely concerned” that the inequality in access seen with Covid vaccines would again leave low- and middle-income countries “pushed to the end of the queue”. US pharma giant Pfizer’s combination of nirmatrelvir and ritonavir was the “superior choice” of treatment for unvaccinated, elderly or immunocompromised people with Covid,…

Read More

Pfizer to provide 10 mln courses of COVID pill to developing countries -the Global Fund – ET HealthWorld

By Michael Erman – Pfizer Inc is expected to provide around 10 million courses of its highly effective COVID-19 antiviral treatment Paxlovid to low- and middle-income countries this year, according to an official with the Global Fund, a healthcare NGO working to buy the pills from the drugmaker. The Fund’s head of strategy for policy, Harley Feldbaum, said Pfizer had committed to at least that many doses and could increase shipments later if organizations involved show they are able to distribute the pills well, noting most will be available toward…

Read More

WHO recommends Merck’s COVID pill for high-risk patients – ET HealthWorld

A World Health Organization (WHO) panel on Wednesday backed the use of Merck & Co Inc’s COVID-19 antiviral pill for high-risk patients. The expert panel conditionally recommended the pill, molnupiravir, for patients with non-severe disease who are at high risk of hospitalisation, such as the immunocompromised, the unvaccinated, older people and those with chronic diseases. The recommendation was based on new data from six clinical trials involving 4,796 patients. Since molnupiravir’s U.S. authorization in December, demand for the pill among COVID-19 patients has taken a hit from comparatively low efficacy…

Read More